Ann: Race investor briefing & updated presentation, page-314

The opportunity was identified by @Mason14 in May

Post #:53359090

Sepsis is a systemic inflammatory response syndrome cause by infection that afflicts 18 million people worldwide and is a common cause of death in ICU. Global market value is estimated around USD $5.9B by 2026, an increase from USD $3.2B in 2018 (2). Currently, there are no clinically approved FTO inhibitors for sepsis shock or inflammatory diseases in general.​

​

Although I wonder if the opportunity could be much bigger than the above due to the stats for Sepsis I posted above.